Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AKRO NASDAQ:AXSM NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.81-0.4%$19.99$10.21▼$25.67$4.27B0.433.68 million shs1.92 million shsAKROAkero Therapeutics$50.37-2.2%$49.21$21.34▼$58.40$4.11B-0.151.05 million shs794,299 shsAXSMAxsome Therapeutics$108.41+0.8%$106.61$72.21▼$139.13$5.29B0.46665,005 shs622,917 shsTVTXTravere Therapeutics$15.30+4.8%$16.53$7.93▼$25.29$1.30B0.721.61 million shs1.43 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-0.39%-0.39%-13.59%-8.15%+53.01%AKROAkero Therapeutics-2.23%-2.02%-7.20%+34.82%+126.99%AXSMAxsome Therapeutics+0.85%+5.28%-3.13%+6.63%+29.65%TVTXTravere Therapeutics+4.79%+4.01%-0.13%+6.62%+75.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.1295 of 5 stars3.72.00.00.02.92.53.1AKROAkero Therapeutics3.4454 of 5 stars3.51.00.04.71.30.80.0AXSMAxsome Therapeutics4.7367 of 5 stars4.51.00.04.52.44.20.6TVTXTravere Therapeutics3.3195 of 5 stars4.43.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6755.34% UpsideAKROAkero Therapeutics 3.00Buy$82.5063.79% UpsideAXSMAxsome Therapeutics 3.06Buy$172.3358.96% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$32.14110.08% UpsideCurrent Analyst Ratings BreakdownLatest TVTX, AXSM, AKRO, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$190.007/1/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/11/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$30.006/11/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $32.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.97$0.54 per share33.03$1.48 per share12.03AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AAXSMAxsome Therapeutics$385.69M13.84N/AN/A$1.18 per share91.87TVTXTravere Therapeutics$233.18M5.83N/AN/A$0.76 per share20.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8520.9525.81N/A45.01%47.16%30.51%8/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.77N/A38.44N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)Latest TVTX, AXSM, AKRO, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.04N/AN/AN/A$140.02 millionN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36AKROAkero Therapeutics0.0316.8016.80AXSMAxsome Therapeutics3.482.031.96TVTXTravere Therapeutics9.462.052.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AKROAkero TherapeuticsN/AAXSMAxsome Therapeutics81.49%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AKROAkero Therapeutics7.07%AXSMAxsome Therapeutics22.40%TVTXTravere Therapeutics4.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableAXSMAxsome Therapeutics38049.24 million38.21 millionOptionableTVTXTravere Therapeutics46088.81 million85.20 millionOptionableTVTX, AXSM, AKRO, and ADMA HeadlinesRecent News About These Companies109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLCJuly 8 at 5:37 AM | marketbeat.comLeerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)July 6 at 5:44 AM | insidermonkey.comLeerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)July 6 at 5:09 AM | msn.comQ2 EPS Estimate for Travere Therapeutics Lowered by AnalystJuly 4, 2025 | americanbankingnews.comInsider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of StockJuly 3, 2025 | insidertrades.comQ2 EPS Estimate for Travere Therapeutics Cut by AnalystJuly 3, 2025 | marketbeat.comJula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockJuly 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJuly 2, 2025 | prnewswire.com1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst ReviewsJuly 2, 2025 | benzinga.comTravere Therapeutics (NASDAQ:TVTX) Earns "Buy" Rating from HC WainwrightJuly 2, 2025 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC WainwrightJuly 1, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - MorningstarJune 29, 2025 | morningstar.comMTravere Therapeutics Inc News (TVTX) - Investing.comJune 27, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 23, 2025 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by BrokeragesJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 16, 2025 | accessnewswire.comAEquities Analysts Set Expectations for TVTX FY2025 EarningsJune 16, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TVTX Q2 Earnings?June 16, 2025 | marketbeat.comTravere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdlesJune 15, 2025 | investing.comAssenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)June 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, AXSM, AKRO, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$17.81 -0.07 (-0.39%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$17.86 +0.05 (+0.28%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Akero Therapeutics NASDAQ:AKRO$50.37 -1.15 (-2.23%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$50.38 +0.01 (+0.01%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Axsome Therapeutics NASDAQ:AXSM$108.41 +0.91 (+0.85%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$108.65 +0.24 (+0.22%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Travere Therapeutics NASDAQ:TVTX$15.30 +0.70 (+4.79%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$15.20 -0.10 (-0.65%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.